Centessa Pharmaceuticals (CNTA) Financials

$13.03 +0.36 (+2.84%)

Closing price 04/23/2025 04:00 PM Eastern

Extended Trading

$11.32 -1.71 (-13.12%)

As of 07:24 AM Eastern

Annual Income Statements for Centessa Pharmaceuticals

This table shows Centessa Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-5.06	-11	-218	-148	-233
Consolidated Net Income / (Loss)	-5.06	-11	-216	-151	-236
Net Income / (Loss) Continuing Operations	-5.06	-11	-216	-151	-236
Total Pre-Tax Income	-5.06	-11	-217	-176	-233
Total Operating Income	-5.05	-10	-212	-171	-201
Total Gross Profit	0.00	0.00	0.00	6.85	0.00
Total Revenue	0.00	0.00	0.00	6.85	0.00
Operating Revenue	-	-	0.00	6.85	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	5.05	10	210	178	201
Selling, General & Admin Expense	0.79	1.14	55	54	51
Research & Development Expense	4.26	9.30	155	124	150
Total Other Income / (Expense), net	-0.01	-0.22	-4.69	-4.86	-32
Interest Expense	0.12	0.31	7.28	9.91	44
Interest & Investment Income	0.01	-0.07	0.24	10	14
Other Income / (Expense), net	0.11	0.16	2.34	-5.43	-1.69
Income Tax Expense	0.00	0.00	-0.75	-25	2.84
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	2.19	-5.98	-5.44
Basic Earnings per Share	$0.00	$0.00	($2.31)	($1.57)	($2.06)
Weighted Average Basic Shares Outstanding	0.00	0.00	93.40M	96.18M	114.47M
Diluted Earnings per Share	$0.00	$0.00	($2.31)	($1.57)	($2.06)
Weighted Average Diluted Shares Outstanding	0.00	0.00	93.40M	96.18M	114.47M
Weighted Average Basic & Diluted Shares Outstanding	-	-	94.96M	100.31M	133.18M

This table shows Centessa Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-54	-45	-50	-23	-39	-36	-38	-44	-42	-109
Consolidated Net Income / (Loss)	-54	-43	-51	-25	-39	-37	-38	-44	-43	-111
Net Income / (Loss) Continuing Operations	-54	-43	-51	-25	-39	-37	-38	-44	-43	-111
Total Pre-Tax Income	-54	-44	-50	-49	-41	-36	-38	-43	-42	-110
Total Operating Income	-49	-42	-49	-47	-40	-35	-36	-44	-46	-75
Total Operating Expenses	49	40	49	47	40	42	36	44	46	75
Selling, General & Admin Expense	12	14	16	13	12	12	13	11	13	14
Research & Development Expense	37	28	33	34	28	30	23	33	34	61
Total Other Income / (Expense), net	-4.99	-2.23	-1.16	-1.92	-1.27	-0.52	-1.48	0.87	4.45	-36
Interest Expense	1.92	2.20	2.35	2.45	2.54	2.57	2.53	2.53	2.56	37
Interest & Investment Income	0.08	0.04	2.53	2.06	2.95	2.93	2.59	3.24	3.34	4.85
Other Income / (Expense), net	-3.14	-0.07	-1.35	-1.53	-1.68	-0.88	-1.54	0.15	3.66	-3.97
Income Tax Expense	-0.14	-0.66	0.68	-24	-2.83	1.14	0.48	0.71	0.61	1.05
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	1.11	-	-1.80	-0.78	0.33	-3.74	-0.26	-0.03	-0.91	-4.24
Basic Earnings per Share	($0.57)	($0.45)	($0.53)	($0.26)	($0.40)	($0.38)	($0.38)	($0.40)	($0.37)	($0.91)
Weighted Average Basic Shares Outstanding	94.33M	93.40M	94.94M	95.16M	96.65M	96.18M	99.89M	109.49M	116.25M	114.47M
Diluted Earnings per Share	($0.57)	($0.45)	($0.53)	($0.26)	($0.40)	($0.38)	($0.38)	($0.40)	($0.37)	($0.91)
Weighted Average Diluted Shares Outstanding	94.33M	93.40M	94.94M	95.16M	96.65M	96.18M	99.89M	109.49M	116.25M	114.47M
Weighted Average Basic & Diluted Shares Outstanding	94.60M	94.96M	95.17M	97.40M	97.63M	100.31M	113.04M	113.31M	131.85M	133.18M

This table details how cash moves in and out of Centessa Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2022	2023	2024
Net Change in Cash & Equivalents	3.70	-9.34	-201	-266	255
Net Cash From Operating Activities	-5.83	-11	-201	-160	-142
Net Cash From Continuing Operating Activities	-5.83	-11	-201	-160	-142
Net Income / (Loss) Continuing Operations	-5.06	-11	-216	-151	-236
Consolidated Net Income / (Loss)	-5.06	-11	-216	-151	-236
Depreciation Expense	0.01	0.00	0.13	0.81	0.94
Non-Cash Adjustments To Reconcile Net Income	0.24	0.52	21	33	68
Changes in Operating Assets and Liabilities, net	-1.01	-0.49	-5.52	-43	25
Net Cash From Investing Activities	0.00	0.00	-0.93	-127	31
Net Cash From Continuing Investing Activities	0.00	0.00	-0.93	-127	31
Purchase of Property, Plant & Equipment	0.00	0.00	-1.14	-0.17	-0.03
Purchase of Investments	-	-	0.00	-265	-141
Sale and/or Maturity of Investments	-	-	0.00	138	172
Net Cash From Financing Activities	9.01	1.36	0.46	21	365
Net Cash From Continuing Financing Activities	9.01	1.36	0.46	21	365
Repayment of Debt	0.00	0.00	-0.26	0.00	-115
Issuance of Debt	3.84	1.36	-	0.00	109
Issuance of Common Equity	0.00	0.00	0.00	21	360
Other Financing Activities, net	0.00	0.00	0.72	0.31	11
Effect of Exchange Rate Changes	0.52	-0.08	-0.42	0.62	1.23
Cash Interest Paid	0.00	0.00	7.28	9.91	10
Cash Income Taxes Paid	-	-	1.30	2.94	0.08

This table details how cash moves in and out of Centessa Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-39	-51	-134	-115	26	-43	-9.81	9.15	268	-12
Net Cash From Operating Activities	-39	-52	-48	-44	-37	-31	-37	-41	-21	-43
Net Cash From Continuing Operating Activities	-39	-52	-48	-44	-37	-31	-37	-41	-21	-43
Net Income / (Loss) Continuing Operations	-54	-43	-51	-25	-39	-37	-38	-44	-43	-111
Consolidated Net Income / (Loss)	-54	-43	-51	-25	-39	-37	-38	-44	-43	-111
Depreciation Expense	0.04	0.04	0.09	0.24	0.24	0.25	0.24	0.24	0.24	0.23
Non-Cash Adjustments To Reconcile Net Income	7.83	8.22	8.99	6.82	8.39	9.22	9.33	8.39	7.73	43
Changes in Operating Assets and Liabilities, net	6.93	-17	-6.20	-26	-7.37	-3.67	-8.81	-5.39	13	26
Net Cash From Investing Activities	-0.02	-0.45	-86	-71	49	-18	17	-55	45	25
Net Cash From Continuing Investing Activities	-0.02	-0.45	-86	-71	49	-18	17	-55	45	25
Sale and/or Maturity of Investments	-	-	0.00	-	86	52	37	65	45	25
Net Cash From Financing Activities	0.22	0.09	0.00	0.01	15	6.36	10	105	246	2.96
Net Cash From Continuing Financing Activities	0.22	0.09	0.00	0.01	15	6.36	10	105	246	2.96
Repayment of Debt	-	-	-	-	-	-	-	-	-0.97	-112
Issuance of Common Equity	-	-	0.00	-	15	6.24	9.66	107	243	-0.03
Other Financing Activities, net	0.22	0.09	0.00	0.01	0.18	0.12	0.84	0.80	4.25	5.34
Effect of Exchange Rate Changes	-0.44	0.72	0.52	0.38	0.22	-0.50	0.22	-0.12	-1.90	3.03
Cash Interest Paid	1.92	2.20	2.34	2.45	2.54	2.57	2.53	2.52	2.56	2.47
Cash Income Taxes Paid	-	0.44	0.14	2.57	0.24	-0.00	0.00	0.00	0.01	0.07

This table presents Centessa Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Total Assets	12	630	444	360	577
Total Current Assets	11	629	438	315	536
Cash & Equivalents	7.23	595	394	128	383
Short-Term Investments	-	-	-	129	99
Prepaid Expenses	1.31	18	20	21	10
Other Current Assets	-	-	-	-	44
Plant, Property, & Equipment, net	0.00	0.16	1.17	1.04	0.74
Total Noncurrent Assets	0.55	0.70	1.88	44	40
Noncurrent Deferred & Refundable Income Taxes	-	-	-	30	27
Other Noncurrent Operating Assets	0.55	-	-	14	13
Total Liabilities & Shareholders' Equity	12	630	444	360	577
Total Liabilities	8.62	138	108	124	175
Total Current Liabilities	8.62	25	38	39	58
Accounts Payable	1.03	8.07	14	12	7.14
Accrued Expenses	1.05	17	25	28	51
Total Noncurrent Liabilities	0.00	113	70	85	117
Long-Term Debt	0.00	76	70	76	109
Other Noncurrent Operating Liabilities	0.00	38	0.00	8.92	8.32
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-22	492	336	236	402
Total Preferred & Common Equity	0.00	492	336	236	402
Total Common Equity	-22	492	336	236	402
Common Stock	-22	877	940	988	1,386
Retained Earnings	0.00	-386	-602	-753	-989
Accumulated Other Comprehensive Income / (Loss)	0.00	0.69	-1.50	1.49	4.21

This table presents Centessa Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	479	404	393	377	328	399	610
Total Current Assets	477	384	350	332	284	356	568
Cash & Equivalents	445	260	145	171	118	127	395
Short-Term Investments	-	86	158	110	112	167	123
Prepaid Expenses	12	18	20	23	18	19	16
Current Deferred & Refundable Income Taxes	20	20	27	28	36	42	34
Plant, Property, & Equipment, net	0.55	1.22	1.15	1.10	0.95	0.90	0.82
Total Noncurrent Assets	1.81	18	41	44	43	42	41
Noncurrent Deferred & Refundable Income Taxes	-	-	27	30	29	29	27
Other Noncurrent Operating Assets	-	18	15	14	14	14	13
Total Liabilities & Shareholders' Equity	479	404	393	377	328	399	610
Total Liabilities	106	111	116	118	113	112	111
Total Current Liabilities	38	30	34	35	27	27	26
Accounts Payable	11	14	11	11	7.50	5.32	7.44
Accrued Expenses	27	15	23	24	20	21	19
Total Noncurrent Liabilities	68	81	82	83	86	85	84
Long-Term Debt	68	72	73	74	77	77	76
Other Noncurrent Operating Liabilities	0.04	9.31	9.15	9.02	8.77	8.63	8.47
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	373	293	277	259	215	287	499
Total Preferred & Common Equity	373	293	277	259	215	287	499
Total Common Equity	373	293	277	259	215	287	499
Common Stock	933	946	953	975	1,005	1,120	1,374
Retained Earnings	-559	-653	-677	-716	-791	-835	-877
Accumulated Other Comprehensive Income / (Loss)	-1.70	-0.60	0.95	0.78	1.62	1.60	2.10

This table displays calculated financial ratios and metrics derived from Centessa Pharmaceuticals' official financial filings.

Metric	2019	2020	2022	2023	2024
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	-100.00%
EBITDA Growth	0.00%	-108.11%	0.00%	16.15%	-14.72%
EBIT Growth	0.00%	-107.86%	0.00%	15.82%	-14.73%
NOPAT Growth	0.00%	-106.61%	0.00%	19.31%	-17.38%
Net Income Growth	0.00%	-110.69%	0.00%	30.12%	-56.04%
EPS Growth	0.00%	0.00%	0.00%	32.03%	-31.21%
Operating Cash Flow Growth	0.00%	-82.49%	0.00%	20.05%	11.41%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	32.50%
Invested Capital Growth	0.00%	0.00%	0.00%	699.00%	-48.90%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-100.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	3.21%	-26.69%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	3.08%	-26.52%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	3.62%	-24.37%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	4.02%	-46.19%
EPS Q/Q Growth	0.00%	0.00%	0.00%	4.27%	-34.64%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	11.34%	-9.02%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	3.27%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	6.43%	-49.80%
Profitability Metrics	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	100.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	-2,566.77%	0.00%
Operating Margin	0.00%	0.00%	0.00%	-2,499.39%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	-2,578.59%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	-2,204.65%	0.00%
Tax Burden Percent	100.00%	100.00%	99.66%	85.78%	101.22%
Interest Burden Percent	102.28%	103.68%	103.35%	99.68%	114.88%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-384.73%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-372.50%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	331.94%	0.00%
Return on Equity (ROE)	0.00%	-344.19%	-52.24%	-52.79%	-73.93%
Cash Return on Invested Capital (CROIC)	0.00%	-1,175.70%	0.00%	-540.24%	-271.56%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	-43.93%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	-37.56%	0.00%
Return on Common Equity (ROCE)	0.00%	2,491.21%	-52.24%	-52.79%	-73.93%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	-64.32%	-63.95%	-58.71%
Net Operating Profit after Tax (NOPAT)	-3.54	-7.31	-149	-120	-141
NOPAT Margin	0.00%	0.00%	0.00%	-1,749.57%	0.00%
Net Nonoperating Expense Percent (NNEP)	0.00%	-419.38%	-20.54%	-12.23%	-34.30%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-38.44%	-27.57%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	784.05%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	1,815.34%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	2,599.39%	0.00%
Earnings before Interest and Taxes (EBIT)	-4.95	-10	-210	-177	-203
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.94	-10	-210	-176	-202
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.86	3.24	4.78
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.86	3.24	4.78
Price to Revenue (P/Rev)	0.00	0.00	0.00	111.71	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	216.24	0.00	10.56	54.55
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	85.32	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	1.82	0.21	0.32	0.27
Long-Term Debt to Equity	0.00	0.00	0.21	0.32	0.27
Financial Leverage	0.00	-0.52	-0.98	-0.89	-0.87
Leverage Ratio	0.00	3.78	1.30	1.41	1.47
Compound Leverage Factor	0.00	3.92	1.34	1.40	1.69
Debt to Total Capital	0.00%	64.49%	17.19%	24.27%	21.34%
Short-Term Debt to Total Capital	0.00%	64.49%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	17.19%	24.27%	21.34%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	292.50%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-257.00%	82.81%	75.73%	78.66%
Debt to EBITDA	0.00	-0.55	-0.33	-0.43	-0.54
Net Debt to EBITDA	0.00	0.16	1.54	1.03	1.85
Long-Term Debt to EBITDA	0.00	0.00	-0.33	-0.43	-0.54
Debt to NOPAT	0.00	-0.77	-0.47	-0.63	-0.77
Net Debt to NOPAT	0.00	0.22	2.18	1.51	2.65
Long-Term Debt to NOPAT	0.00	0.00	-0.47	-0.63	-0.77
Altman Z-Score	0.00	18.25	-0.77	0.10	4.00
Noncontrolling Interest Sharing Ratio	0.00%	823.79%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.00	1.30	11.42	8.00	9.25
Quick Ratio	0.00	0.84	10.27	6.51	8.31
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-8.81	0.00	-168	-114
Operating Cash Flow to CapEx	0.00%	0.00%	-17,638.17%	-94,876.92%	-417,808.82%
Free Cash Flow to Firm to Interest Expense	0.00	-28.41	0.00	-17.00	-2.57
Operating Cash Flow to Interest Expense	-49.36	-34.29	-27.56	-16.19	-3.21
Operating Cash Flow Less CapEx to Interest Expense	-49.36	-34.29	-27.72	-16.20	-3.22
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.02	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	6.21	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	0.00	1.50	6.93	55	28
Invested Capital Turnover	0.00	0.00	0.00	0.22	0.00
Increase / (Decrease) in Invested Capital	0.00	1.50	0.00	48	-27
Enterprise Value (EV)	0.00	324	-34	585	1,544
Market Capitalization	300	300	290	766	1,917
Book Value per Share	$0.00	($1.49)	$3.55	$2.42	$3.05
Tangible Book Value per Share	$0.00	($1.49)	$3.55	$2.42	$3.05
Total Capital	0.00	8.73	406	312	510
Total Debt	0.00	5.63	70	76	109
Total Long-Term Debt	0.00	0.00	70	76	109
Net Debt	0.00	-1.60	-324	-181	-373
Capital Expenditures (CapEx)	0.00	0.00	1.14	0.17	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	0.95	5.77	19	-3.77
Debt-free Net Working Capital (DFNWC)	0.00	8.17	399	276	478
Net Working Capital (NWC)	0.00	2.55	399	276	478
Net Nonoperating Expense (NNE)	1.52	3.36	68	31	95
Net Nonoperating Obligations (NNO)	0.00	-1.60	-329	-181	-373
Total Depreciation and Amortization (D&A)	0.01	0.00	0.13	0.81	0.94
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	279.56%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	4,023.16%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	4,023.16%	0.00%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($2.31)	($1.57)	($2.06)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	93.40M	96.18M	114.47M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($2.31)	($1.57)	($2.06)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	93.40M	96.18M	114.47M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	94.96M	100.31M	133.18M
Normalized Net Operating Profit after Tax (NOPAT)	-3.54	-7.31	-149	-120	-141
Normalized NOPAT Margin	0.00%	0.00%	0.00%	-1,749.57%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	-2,570.28%	0.00%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	-41.93	-33.18	-28.85	-17.84	-4.59
NOPAT to Interest Expense	-29.98	-23.57	-20.42	-12.10	-3.19
EBIT Less CapEx to Interest Expense	-41.93	-33.18	-29.00	-17.86	-4.59
NOPAT Less CapEx to Interest Expense	-29.98	-23.57	-20.57	-12.12	-3.19
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Centessa Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-29.63%	0.00%	5.40%	23.35%	20.12%	13.99%	25.43%	9.77%	-2.06%	-118.70%
EBIT Growth	-29.71%	0.00%	5.28%	23.01%	19.71%	13.48%	25.08%	9.72%	-2.04%	-117.85%
NOPAT Growth	-27.96%	0.00%	8.16%	31.27%	17.99%	15.44%	26.16%	6.46%	-15.41%	-112.01%
Net Income Growth	-34.17%	0.00%	6.94%	61.51%	28.26%	14.68%	24.98%	-76.07%	-10.14%	-202.22%
EPS Growth	-26.67%	0.00%	11.67%	62.32%	29.82%	15.56%	28.30%	-53.85%	7.50%	-139.47%
Operating Cash Flow Growth	0.00%	0.00%	4.36%	26.41%	4.34%	39.78%	22.06%	7.90%	42.80%	-37.84%
Free Cash Flow Firm Growth	-1,879.79%	0.00%	0.00%	2.59%	-45.52%	0.00%	-59.19%	30.68%	57.05%	65.63%
Invested Capital Growth	81.63%	0.00%	88.83%	1,661.18%	1,040.36%	699.00%	231.61%	48.17%	8.34%	-48.90%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	17.27%	20.14%	-20.41%	3.64%	13.79%	14.02%	-4.40%	-16.59%	2.49%	-84.26%
EBIT Q/Q Growth	17.26%	20.12%	-20.52%	3.34%	13.72%	13.92%	-4.36%	-16.47%	2.48%	-83.78%
NOPAT Q/Q Growth	28.34%	15.14%	-17.48%	3.80%	14.48%	12.51%	-2.59%	-21.86%	-5.51%	-60.72%
Net Income Q/Q Growth	16.68%	19.86%	-17.47%	50.93%	-55.30%	4.69%	-3.28%	-15.17%	2.85%	-161.54%
EPS Q/Q Growth	17.39%	21.05%	-17.78%	50.94%	-53.85%	5.00%	0.00%	-5.26%	7.50%	-145.95%
Operating Cash Flow Q/Q Growth	34.72%	-31.92%	7.23%	7.89%	15.14%	16.96%	-20.08%	-8.83%	47.29%	-100.10%
Free Cash Flow Firm Q/Q Growth	25.08%	100.00%	0.00%	-78.23%	-11.92%	14.75%	6.39%	22.39%	30.65%	31.78%
Invested Capital Q/Q Growth	-310.46%	225.26%	168.74%	148.60%	12.37%	6.43%	11.54%	11.08%	-17.84%	-49.80%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-522.54%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-513.32%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-526.13%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-537.53%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	99.74%	98.49%	101.35%	50.85%	93.19%	103.21%	101.28%	101.64%	101.45%	100.95%
Interest Burden Percent	103.54%	105.19%	99.63%	100.81%	99.02%	98.99%	99.84%	98.37%	98.17%	140.40%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-79.02%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	-74.23%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	66.15%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-52.24%	-54.93%	-49.57%	-49.79%	-12.87%	0.00%	0.00%	0.00%	-73.93%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-540.24%	-383.25%	-228.15%	-216.71%	-271.56%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	-8.96%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	-9.16%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	0.00%	-52.24%	-54.93%	-49.57%	-49.79%	-12.87%	0.00%	0.00%	0.00%	-73.93%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	-72.43%	-62.42%	-60.69%	0.00%	-64.33%	-54.83%	-32.31%	0.00%
Net Operating Profit after Tax (NOPAT)	-34	-29	-34	-33	-28	-25	-25	-31	-32	-52
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-359.33%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.08%	-4.27%	-4.43%	2.48%	-3.59%	-4.79%	-5.97%	-5.81%	-3.10%	-21.34%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-7.89%	-	-	-	-10.23%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	179.70%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	433.62%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	613.32%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-52	-42	-50	-49	-42	-36	-38	-44	-43	-79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-52	-42	-50	-48	-42	-36	-37	-44	-43	-78
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.02	0.86	1.25	2.13	2.41	3.24	5.25	3.45	3.72	4.78
Price to Tangible Book Value (P/TBV)	1.02	0.86	1.25	2.13	2.41	3.24	5.25	3.45	3.72	4.78
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	111.71	164.71	144.27	271.25	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	4.88	7.75	8.03	10.56	15.79	11.22	25.11	54.55
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	85.32	142.33	112.41	206.65	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.18	0.21	0.24	0.27	0.29	0.32	0.36	0.27	0.15	0.27
Long-Term Debt to Equity	0.18	0.21	0.24	0.27	0.29	0.32	0.36	0.27	0.15	0.27
Financial Leverage	-1.04	-0.98	-0.96	-0.93	-0.93	-0.89	-0.84	-0.80	-0.86	-0.87
Leverage Ratio	1.18	1.30	1.27	1.31	1.35	1.41	1.44	1.40	1.30	1.47
Compound Leverage Factor	1.23	1.36	1.27	1.32	1.34	1.39	1.44	1.38	1.28	2.06
Debt to Total Capital	15.46%	17.19%	19.62%	20.95%	22.20%	24.27%	26.30%	21.05%	13.17%	21.34%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	15.46%	17.19%	19.62%	20.95%	22.20%	24.27%	26.30%	21.05%	13.17%	21.34%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	84.54%	82.81%	80.38%	79.05%	77.80%	75.73%	73.70%	78.95%	86.83%	78.66%
Debt to EBITDA	0.00	-0.33	-0.35	-0.38	-0.41	-0.43	-0.47	-0.48	-0.48	-0.54
Net Debt to EBITDA	0.00	1.54	1.33	1.20	1.14	1.03	0.94	1.38	2.78	1.85
Long-Term Debt to EBITDA	0.00	-0.33	-0.35	-0.38	-0.41	-0.43	-0.47	-0.48	-0.48	-0.54
Debt to NOPAT	0.00	-0.47	-0.49	-0.56	-0.59	-0.63	-0.69	-0.70	-0.67	-0.77
Net Debt to NOPAT	0.00	2.18	1.89	1.76	1.67	1.51	1.38	2.01	3.91	2.65
Long-Term Debt to NOPAT	0.00	-0.47	-0.49	-0.56	-0.59	-0.63	-0.69	-0.70	-0.67	-0.77
Altman Z-Score	0.00	0.48	0.36	1.18	1.10	1.39	3.20	3.02	8.92	4.71
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	12.49	11.42	12.95	10.35	9.51	8.00	10.37	13.29	21.52	9.25
Quick Ratio	11.65	10.27	11.66	8.96	8.05	6.51	8.39	11.02	19.63	8.31
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-59	0.00	-43	-77	-86	-73	-68	-53	-37	-25
Operating Cash Flow to CapEx	-244,300.00%	-7,908.59%	-54,361.36%	-440,620.00%	-86,958.14%	-110,892.86%	0.00%	0.00%	-62,908.82%	0.00%
Free Cash Flow to Firm to Interest Expense	-30.65	0.00	-18.33	-31.27	-33.74	-28.44	-27.05	-21.03	-14.40	-0.69
Operating Cash Flow to Interest Expense	-20.34	-23.42	-20.40	-17.98	-14.72	-12.08	-14.74	-16.07	-8.36	-1.17
Operating Cash Flow Less CapEx to Interest Expense	-20.35	-23.71	-20.44	-17.99	-14.73	-12.09	-14.74	-16.07	-8.38	-1.17
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.02	0.02	0.02	0.01	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	6.21	6.31	6.69	7.13	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-5.54	6.93	19	46	52	55	62	69	56	28
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.22	0.17	0.12	0.13	0.00
Increase / (Decrease) in Invested Capital	25	0.00	8.77	44	58	48	43	22	4.34	-27
Enterprise Value (EV)	2.56	-34	91	359	418	585	975	770	1,416	1,544
Market Capitalization	379	290	366	589	625	766	1,129	989	1,859	1,917
Book Value per Share	$3.95	$3.55	$3.09	$2.91	$2.66	$2.42	$2.15	$2.54	$4.40	$3.05
Tangible Book Value per Share	$3.95	$3.55	$3.09	$2.91	$2.66	$2.42	$2.15	$2.54	$4.40	$3.05
Total Capital	441	406	365	350	333	312	292	363	575	510
Total Debt	68	70	72	73	74	76	77	77	76	109
Total Long-Term Debt	68	70	72	73	74	76	77	77	76	109
Net Debt	-377	-324	-275	-230	-207	-181	-153	-218	-443	-373
Capital Expenditures (CapEx)	0.02	0.65	0.09	0.01	0.04	0.03	0.00	0.00	0.03	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-6.04	5.77	8.42	13	16	19	27	34	24	-3.77
Debt-free Net Working Capital (DFNWC)	439	399	355	317	297	276	257	329	542	478
Net Working Capital (NWC)	439	399	355	317	297	276	257	329	542	478
Net Nonoperating Expense (NNE)	20	14	17	-8.03	11	12	13	13	10	59
Net Nonoperating Obligations (NNO)	-378	-329	-275	-230	-207	-181	-153	-218	-443	-373
Total Depreciation and Amortization (D&A)	0.04	0.04	0.09	0.24	0.24	0.25	0.24	0.24	0.24	0.23
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	279.56%	392.00%	494.88%	343.05%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	4,023.16%	3,750.78%	4,797.13%	7,908.33%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	4,023.16%	3,750.78%	4,797.13%	7,908.33%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.57)	($0.45)	($0.53)	($0.26)	($0.40)	($0.38)	($0.38)	($0.40)	($0.37)	($0.91)
Adjusted Weighted Average Basic Shares Outstanding	94.33M	93.40M	94.94M	95.16M	96.65M	96.18M	99.89M	109.49M	116.25M	114.47M
Adjusted Diluted Earnings per Share	($0.57)	($0.45)	($0.53)	($0.26)	($0.40)	($0.38)	($0.38)	($0.40)	($0.37)	($0.91)
Adjusted Weighted Average Diluted Shares Outstanding	94.33M	93.40M	94.94M	95.16M	96.65M	96.18M	99.89M	109.49M	116.25M	114.47M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	94.60M	94.96M	95.17M	97.40M	97.63M	100.31M	113.04M	113.31M	131.85M	133.18M
Normalized Net Operating Profit after Tax (NOPAT)	-34	-29	-34	-33	-28	-25	-25	-31	-32	-52
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-359.33%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-520.84%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-27.14	-18.93	-21.42	-19.81	-16.48	-14.03	-14.88	-17.36	-16.72	-2.15
NOPAT to Interest Expense	-17.86	-13.23	-14.59	-13.43	-11.08	-9.58	-9.99	-12.19	-12.70	-1.43
EBIT Less CapEx to Interest Expense	-27.15	-19.22	-21.45	-19.82	-16.50	-14.04	-14.88	-17.36	-16.73	-2.15
NOPAT Less CapEx to Interest Expense	-17.86	-13.52	-14.63	-13.44	-11.09	-9.59	-9.99	-12.19	-12.72	-1.43
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Centessa Pharmaceuticals' Financials

When does Centessa Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Centessa Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Centessa Pharmaceuticals' net income changed over the last 4 years?

Centessa Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$235.76 million in 2024, rising from -$5.06 million in 2019. The previous period was -$151.09 million in 2023.

What is Centessa Pharmaceuticals's operating income?

Centessa Pharmaceuticals's total operating income in 2024 was -$201.06 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $201.06 million

How has Centessa Pharmaceuticals revenue changed over the last 4 years?

Over the last 4 years, Centessa Pharmaceuticals' total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

How much debt does Centessa Pharmaceuticals have?

Centessa Pharmaceuticals' total liabilities were at $175.25 million at the end of 2024, a 41.3% increase from 2023, and a 1,933.3% increase since 2020.

How much cash does Centessa Pharmaceuticals have?

In the past 4 years, Centessa Pharmaceuticals' cash and equivalents has ranged from $7.23 million in 2020 to $595.08 million in 2021, and is currently $383.22 million as of their latest financial filing in 2024.

How has Centessa Pharmaceuticals' book value per share changed over the last 4 years?

Over the last 4 years, Centessa Pharmaceuticals' book value per share changed from 0.00 in 2019 to 3.05 in 2024, a change of 304.6%.

Related Companies

This page (NASDAQ:CNTA) was last updated on 4/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Centessa Pharmaceuticals (CNTA) Financials

Frequently Asked Questions About Centessa Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Centessa Pharmaceuticals (CNTA) Financials

Annual Income Statements for Centessa Pharmaceuticals

Quarterly Income Statements for Centessa Pharmaceuticals

Annual Cash Flow Statements for Centessa Pharmaceuticals

Quarterly Cash Flow Statements for Centessa Pharmaceuticals

Annual Balance Sheets for Centessa Pharmaceuticals

Quarterly Balance Sheets for Centessa Pharmaceuticals

Annual Metrics and Ratios for Centessa Pharmaceuticals

Quarterly Metrics and Ratios for Centessa Pharmaceuticals

Frequently Asked Questions About Centessa Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools